NexMab™ ADC Technology
ALTEOGEN’s NexMab™ is an ADC(Antibody Drug Conjugate) technology conjugating the anti-cancer chemical drugs to an antibody protein. ADC technology is a technology for the next generation anti-cancer therapeutics, which increase the effectiveness and reduces side effects of the anti-cancer cells directy.
NexMab™ makes the anti-cancer chemical drugs to conjugate to the C-terminus of antibody protein site-spceifically, this can control the conjugation site and the number of conjugation.
ALTEOGEN is developing an anti-breast cancer therapeutic (Trastuzumab-drug conjugate) with NexMab™ technology, and which can be applied for various antibody therapeutic bio betters.